Biosyent Inc V.RX

Alternate Symbol(s): BIOYF

Healthcare

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Company’s business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.

TSXV:RX - Post by User

Biosyent Inc

Bullboard Posts

Comment by overnouton Oct 05, 2020 11:20am

81 Views

Post# 31666683

RE:NR - patented FeraMAX delivery system

The market seems slow to understand or even acknowledge what is happening at Biosyent right now.
In the past couple of months we have had a new product launch, (Tibella) the announcement of a new product licensing which is already Health Canada aprroved, (women's healthcare product), an upgrade of the Feramax product and the coming Combogesic launch. All of these should lead to growing top line revenues over the next few quarters.

Market reaction, down 10% from recent highs. Hmm

Bullboard Posts

Visionstate set to leverage success in the U.S. market